9549918

4 known cases. View patent page →

Veloxis Pharmaceuticals AS v. Zydus Cadila et al.

Open

Docket:: 1:26-cv-00467
Court:: Delaware District Court
Forum:: District Court
Filed:: 2026-04-23
Cause:: Infringement
Industry:: Medical (M)

Patents:11419823 10864199 8685998 8664239 11123331 12403095 10166190 11110081 12083103 9549918

π Veloxis Pharmaceuticals AS Δ Zydus Cadila Δ Zydus Lifesciences Ltd

Infringed product

The accused products are the 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets sold under the brand name ENVARSUS XR.

Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc.

ongoing

Docket:: 1:25-cv-00458
Court:: U.S. District Court for the District of Delaware
Filed:: 2025-04-14

Patents:9549918

π Veloxis Pharmaceuticals, Inc.Δ Glenmark Pharmaceuticals Inc.

This Hatch-Waxman Act litigation against Glenmark Pharmaceuticals is currently listed as ongoing.

Veloxis Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Ltd.

settled

Court:: U.S. District Court for the District of Delaware

Patents:9549918

π Veloxis Pharmaceuticals Inc.Δ Sun Pharmaceutical Industries Ltd.

This case was settled in April 2026, averting a bench trial. The agreement prevents Sun from launching a generic version of Envarsus XR until May 2028.

Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. et al.

outcome not detailed

Docket:: 1:22-cv-00909
Court:: U.S. District Court for the District of Delaware
Filed:: 2022-07-07

Patents:9549918

π Veloxis Pharmaceuticals, Inc.Δ Accord Healthcare, Inc.Δ Intas Pharmaceuticals LTD

The complaint alleged that the defendants' ANDA for generic tacrolimus extended-release tablets infringed on six Veloxis patents, including the '918 patent. Veloxis sought to block the manufacturing and marketing of the generic product.